Madrigal Pharmaceuticals (MDGL) News Today → The #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique Way (From Smallcaps Daily) (Ad) Free MDGL Stock Alerts $217.96 -17.61 (-7.48%) (As of 05/7/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineBuy Rating Affirmed for Madrigal Pharmaceuticals Amid Strong Rezdiffra Launch and Solid Financialsmarkets.businessinsider.com - May 7 at 10:16 PMMadrigal sees ‘tremendous interest’ in new NASH drug Rezdiffraseekingalpha.com - May 7 at 5:12 PMMDGL Stock Earnings: Madrigal Pharmaceuticals Misses EPS for Q1 2024msn.com - May 7 at 5:12 PMMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Down to $235.57marketbeat.com - May 7 at 3:22 PMMadrigal Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Rezdiffra Launchfinance.yahoo.com - May 7 at 9:58 AMMadrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updatesglobenewswire.com - May 7 at 7:00 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Shares Up 8.2%americanbankingnews.com - May 5 at 6:50 AMCalifornia Public Employees Retirement System Reduces Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - May 5 at 5:12 AMMadrigal Pharmaceuticals (MDGL) Set to Announce Quarterly Earnings on Tuesdayamericanbankingnews.com - May 5 at 4:46 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Average Rating of "Moderate Buy" by Brokeragesamericanbankingnews.com - May 2 at 2:30 AMMadrigal: Rezdiffra Launch Gets Underway, The Only Competition Is Off-Labelseekingalpha.com - April 30 at 9:24 PMMadrigal Pharmaceuticals (MDGL) Scheduled to Post Quarterly Earnings on Tuesdaymarketbeat.com - April 30 at 11:09 AMValidea Detailed Fundamental Analysis - MDGLnasdaq.com - April 28 at 7:59 AMSagimet Biosciences' Denifanstat Imminent Phase 3: A Promising Investment Opportunityseekingalpha.com - April 26 at 2:15 PMMadrigal Pharmaceuticals to Unveil First-Quarter Results, Hosts Live Webcastmsn.com - April 25 at 1:07 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6%marketbeat.com - April 24 at 7:14 PMMadrigal Statement on the Passing of Dr. Stephen Harrisonglobenewswire.com - April 24 at 4:00 PMMadrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantageseekingalpha.com - April 24 at 1:02 PMMadrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024finance.yahoo.com - April 23 at 8:19 AMUnited Healthcare’s Favorable Insurance Coverage of Rezdiffra Boosts Madrigal Pharmaceuticals Buy Ratingmarkets.businessinsider.com - April 22 at 8:53 PMMadrigal Pharmaceuticals (NASDAQ:MDGL) Earns Underperform Rating from Analysts at Bank of Americamarketbeat.com - April 22 at 8:29 AMKnights of Columbus Asset Advisors LLC Acquires 4,386 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - April 21 at 6:39 AMMadrigal Pharmaceuticals Welcomes New Employees with Equity Awardsmsn.com - April 20 at 6:14 AMMadrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Down 3.3%marketbeat.com - April 17 at 12:20 PMMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 16 at 4:05 PM7 Stocks Analysts Are Loving Right Now (And You Should Too): April 2024investorplace.com - April 15 at 7:52 AM211,488 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by AlpInvest Partners B.V.marketbeat.com - April 14 at 8:45 PMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CMO Rebecca Taub Sells 2,676 Sharesinsidertrades.com - April 11 at 6:37 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 26,270 Shares of Stockinsidertrades.com - April 11 at 6:16 AMMadrigal Pharmaceuticals Launches Rezdiffra, a Pioneer in NASH Treatmentmsn.com - April 10 at 10:34 PM2 Under-the-Radar Growth Stocks to Considermsn.com - April 10 at 12:33 PM2 Under-the-Radar Growth Stocks to Considerfool.com - April 10 at 10:15 AMMoody Aldrich Partners LLC Sells 4,356 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - April 10 at 8:54 AMMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosisfinance.yahoo.com - April 9 at 8:42 AMJames M. Daly Sells 32,489 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Stockinsidertrades.com - April 9 at 4:22 AMMadrigal Pharmaceuticals, Inc.cnn.com - April 7 at 1:19 AMMadrigal Pharmaceuticals Awards Equity to New Employees as Inducementmsn.com - April 6 at 8:18 PMInsider Selling: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Sells 18,710 Shares of Stockinsidertrades.com - April 6 at 7:30 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Paul A. Friedman Sells 18,710 Sharesmarketbeat.com - April 5 at 9:06 PMBetter Booming Biotech Stock: Madrigal Pharmaceuticals vs. Viking Therapeuticsfool.com - April 5 at 7:15 AMMadrigal Pharmaceuticals Inc Director Kenneth Bate Sells 32,489 Sharesfinance.yahoo.com - April 4 at 8:35 AMMadrigal Pharmaceuticals Inc Director Richard Levy Sells 11,000 Sharesfinance.yahoo.com - April 4 at 8:35 AMMadrigal Pharmaceuticals Inc Director James Daly Sells 32,489 Sharesfinance.yahoo.com - April 4 at 8:35 AMMadrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Director Richard S. Levy Sells 11,000 Sharesinsidertrades.com - April 4 at 5:59 AMMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - April 3 at 4:05 PM1 No-Brainer Growth Stock to Buy Nowfool.com - April 3 at 8:45 AMViking Therapeutics: Future Weight Loss Heavyweight?seekingalpha.com - April 2 at 7:31 AMAssenagon Asset Management S.A. Cuts Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)marketbeat.com - April 2 at 4:38 AMThe 3 Best Biotech Stocks to Buy in April 2024investorplace.com - April 1 at 9:09 PM4,773 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by AMI Asset Management Corpmarketbeat.com - March 30 at 11:30 PM Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address “Crash Insurance” For Your Retirement (Ad)When it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. MDGL Media Mentions By Week MDGL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MDGL News Sentiment▼0.370.38▲Average Medical News Sentiment MDGL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MDGL Articles This Week▼116▲MDGL Articles Average Week Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alkermes News Today Amicus Therapeutics News Today Geron News Today Ionis Pharmaceuticals News Today Rocket Pharmaceuticals News Today Dynavax Technologies News Today Ligand Pharmaceuticals News Today Ironwood Pharmaceuticals News Today MannKind News Today Intercept Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MDGL) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI “wealth window” is closing June 25thParadigm Press[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsStock-Picking AI Predicts #1 Stock of 2024AltimetryElon Musk Secret Crypto Plot ExposedCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
